News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
News Pushback against Kennedy's mRNA decision builds The decision by HHS to cut funding for mRNA vaccines has caused dismay among scientists and public health experts, who have labelled it wrong-headed.
News Rumour mill says Novartis may want to buy Avidity Novartis has made an offer to acquire RNA therapeutic specialist Avidity Biosciences, according to an unconfirmed report.
News RFK Jr cancels $500m in funding for mRNA vaccines RFK Jr is cutting $500m in funding for mRNA vaccines for diseases like flu and COVID-19, but critics say his reasons for doing so are spurious.
News Vertex is smarting from a pain portfolio setback Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.
News Gates Foundation puts $2.5bn into 'ignored' women's health The Gates Foundation is ramping up support for women's health research, pumping $2.5bn into new projects in this 'ignored, underfunded' area of R&D.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
